Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384631
Status:
COMPLETED
Last Update Posted:
2008-02-15
First Post:
2006-10-04
Brief Title:
Intravitreal Bevacizumab for Neovascular Glaucoma
Sponsor:
Shahid Beheshti University of Medical Sciences
Organization:
Shahid Beheshti University of Medical Sciences
Study Overview
Official Title:
Intravitreal Bevacizumab for Neovascular Glaucoma a Randomized Placebo Controlled Clinical Trial
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IVB NVG
Brief Summary:
Several studies have confirmed high levels of vascular endothelial growth factor VEGF in eyes with neovascular glaucoma NVG The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described We aim to evaluate the effect of three intravitreal injections of bevacizumab Avastin 25 mg versus a sham procedure for treatment of NVG Outcome measures include intraocular pressure and extent of iris neovascularization Both study arms will receive conventional treatment for NVG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None